Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2438 Results for "
decrease
" in MedChemExpress (MCE) Product Catalog:
Products (2438)
2438 Results for "decrease" in MCE Product Catalog:
Cat. No.: HY-17609S1
Synonyms: CR-845-d5 hydrochloride; FE-202845-d5 hydrochloride
Difelikefalin-d5 hydrochloride (CR-845-d5 hydrochloride; FE-202845-d5 hydrochloride) is the deuterated-labeled Difelikefalin (HY-17609). Difelikefalin (CR-845; FE-202845) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis .
Cat. No.: HY-178441
연구분야:
PKM2-IN-11 is a PKM2 inhibitor (IC50 = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .
Cat. No.: HY-178694
CAS No.: 120430-77-5
Target:
연구분야:
DC-PRC2in-01 is a potent EZH2-EED interaction inhibitor with an IC50 of 4.21 μM and a Kd of 4.56 μM. DC-PRC2in-01 disrupts the EZH2-EED interaction, leading to degradation of PRC2 core proteins and decrease of H3K27me3 levels, inhibition of PRC2-driven lymphoma cell proliferation, and cell cycle arrest. DC-PRC2in-01 can be used for the research of PRC2-related cancers, such as Diffuse Large B-cell Lymphoma (DLBCL) and follicular lymphoma (FL) .
Cat. No.: HY-179572
Target:
연구분야:
STA-013 is a EphB tyrosine kinase inhibitor. STA-013 shows promising potency against EphB1 (IC50 = 0.69 µM), EphB2 (IC50 = 1.73 µM), and EphB4 (IC50 = 1.02 µM) tyrosine kinases. STA-013 results a inhibition of the EphB phosphorylated signal, coupled with increased p-AKT/AKT signaling, to suggest insulin signaling activation. STA-013 inhibits EphB tyrosine kinase by enhancing insulin receptor beta (IRβ) signaling, and decreasing TGF-β levels in the heart. STA-013 can be used for the study of type 2 diabetes and cardiac complications (diabetic cardiomyopathy) .
Cat. No.: HY-181762
연구분야:
Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a Kd of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease .
Cat. No.: HY-182513
CAS No.: 459842-29-6
Target:
ONO-8539 is an orally active prostanoid EP1 receptor antagonist with competitive, insurmountable binding and slow receptor dissociation for long-duration inhibition. ONO-8539 modulates afferent nerve function related to bladder activity, inhibits detrusor overactivity-related contractions, decreases nonvoiding contractions and voiding duration, and increases uroflow rate with ATP (HY-B2176)-induced detrusor overactivity. ONO-8539 attenuates acid-induced heartburn symptoms, extends time to first heartburn sensation, and prevents primary hypersensitivity after distal esophageal acidification. ONO-8539 can be used for the research of overactive bladder and gastroesophageal reflux disease .
Cat. No.: HY-183257
CAS No.: 1242983-93-2
연구분야:
ATI-1 is an autophagy initiation inhibitor. ATI-1 targets valosin-containing protein (VCP/p97, disrupts its interaction with UFL1, impairs UFMylation homeostasis associated with VCP, promotes polyubiquitination and degradation of Beclin1, and blocks the formation of early autophagosomes. ATI-1 induces synergistic death of autophagy-dependent malignant tumor cells under nutrient deprivation conditions, accompanied by decreased mitochondrial membrane potential, reduced ROS levels and lysosomal stress. ATI-1 exhibits anti-tumor efficacy in a pancreatic adenocarcinoma xenograft mouse model. ATI-1 can be used for the research of pancreatic adenocarcinoma and lung cancer .
Cat. No.: HY-187185
CAS No.: 3050643-44-9
Target:
Sigma-1 receptor antagonist 7 is a selective sigma-1 receptor antagonist capable of crossing the blood-brain barrier, with an IC50 of 12.7 nM against guinea pig σ1R. Sigma-1 receptor antagonist 7 binds to σ1R, and its binding affinity decreases in the presence of Phenytoin (HY-B0448). Sigma-1 receptor antagonist 7 alleviates mechanical and thermal hyperalgesia induced by acute inflammation in rats. Sigma-1 receptor antagonist 7 can be used for research related to hyperalgesia .
Cat. No.: HY-189136
CAS No.: 2086229-19-6
Target:
연구분야:
FCW34 is a cell-permeable, selective Sialyltransferase inhibitor. FCW34 inhibits α2,3-N-linked ST3GALIII (IC50 1.74 μM) and α2,6-N-linked ST6GALI (IC50 3.6 μM), reducing N-glycoprotein sialylation. FCW34 decreases cell migration ability by inhibiting the Talin/Integrin/FAK/Paxillin and Integrin/NFκB signaling pathways. FCW34 significantly inhibits tumor growth, reduces angiogenesis, and suppresses spontaneous lung metastasis in a nude mouse model of breast cancer. FCW34 can be used for research on breast cancer .
Cat. No.: HY-189650
연구분야:
AMPAR/Nav1.2-IN-1 is a blood-brain barrier-penetrant AMPAR inhibitor and Nav1.2 blocker with IC50 values of 12.7 and 7.01 μM, respectively. AMPAR/Nav1.2-IN-1 inhibits AMPA-mediated excitatory currents and neuronal Nav1.2 voltage-gated sodium channels. AMPAR/Nav1.2-IN-1 scavenges free radicals via HAT and SET, increases GSH and SOD while decreasing MDA, and restores GABA-glutamate homeostasis by attenuating glutamate elevation and increasing GABA. AMPAR/Nav1.2-IN-1 can be used for epilepsy research .
Cat. No.: HY-189826
CAS No.: 3106928-52-0
AMC-3-221 is a cereblon-dependent CDK9 PROTAC degrader with a DC50 of 8 nM (MOLM14 AML cells). AMC-3-221 targets CDK9 with an IC50 of 1.7 nM and a Kd of 4.6 nM. AMC-3-221 decreases MCL-1 and c-MYC protein levels as well as MCL-1, c-MYC, and N-MYC RNA levels. AMC-3-221 induces apoptosis and inhibits proliferation in multiple cancer cell lines. AMC-3-221 exhibits proteasome-dependent CDK9 degradation. AMC-3-221 can be used for research on acute myeloid leukemia (AML) .
Cat. No.: HY-190183
CAS No.: 1043812-24-3
Target:
연구분야:
eEF2K Degrader-3 is an eEF2K molecular glue degrader (Kd = 0.831 μM) that recruits βTRCP to mediate ubiquitin-proteasome degradation. eEF2K Degrader-3 triggers rapid downregulation of eEF2K and produces a durable effect. eEF2K Degrader-3 inhibits TNBC cell proliferation, migration, and invasion, suppresses tumor growth and lung metastasis in mouse models, decreases vimentin and increases E-cadherin in organoids, and downregulates AURKA and SOX8 downstream of eEF2K degradation. eEF2K Degrader-3 can be used for research on triple-negative breast cancer (TNBC) .
Cat. No.: HY-190711
연구분야:
AChE/BChE/Aβ42-IN-1 is an inhibitor that inhibits AChE, BChE, and β-amyloid (Aβ42) with IC50 values of 7.01 μM, 5.39 μM, and 4.47 μM, respectively. AChE/BChE/Aβ42-IN-1 reduces NF-κB p65 phosphorylation, attenuates LPS/Aβ42-induced neurotoxicity, increases microglial viability, decreases reactive oxygen species (ROS), pro-inflammatory cytokines, and nitric oxide, and attenuates microglial activation. AChE/BChE/Aβ42-IN-1 can be used for research on Alzheimer's disease .
Cat. No.: HY-19205A
CAS No.: 193739-23-0
Synonyms: LDP-392
CMI-392 (LDP-392) is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
Cat. No.: HY-B1114A
CAS No.: 62783-47-5
Synonyms: AR-DF 26 sodium
Gliquidone sodium (AR-DF 26 sodium) can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone sodium significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone sodium can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone sodium also exhibits good anticancer activity in lung carcinoma cells. Gliquidone sodium has antioxidant property. Gliquidone sodium can be studied in research for type 2 diabetes and cancers .
Cat. No.: HY-D1422
CAS No.: 1445108-32-6
Synonyms: BDNCA-346
Target:
연구분야:
ER Tracker Yellow (BDNCA-346) is a Fluorescent probe for targeted visualization of temperature at the endoplasmic reticulum. Its detection mechanism depends on temperature, with fluorescence intensity decreasing at higher temperatures due to preferential non-radiative processes; this intensity reversibly returns to baseline when cooled, provided the probe does not precipitate or degrade. It localizes specifically to the endoplasmic reticulum, where it may covalently attach to biomacromolecules via a thiol-reactive moiety, and its fluorescence remains stable after cell fixation; its fluorescence intensity is unaffected by physiological pH ranges of 5.0–8.0 and free Ca²⁺ concentrations of 0–800 μM. Its excitation/emission wavelength is Ex/Em = 559/581 nm[1].
Cat. No.: HY-D3087
CAS No.: 1966158-27-9
Target:
연구분야:
Lyso-OC is a two-photon fluorescent probe that enables real-time monitoring of autophagy through ultrasensitive detection of lysosomal polarity changes. Lyso-OC possesses a coumarin (HY-N0709) solvatochromic group and a morpholine lysosome-targeting group, allowing selective lysosomal localization in living cells. Lyso-OC emits strong fluorescence in low-polarity lysosomes, whereas in high-polarity autolysosomes formed during autophagy, its fluorescence intensity decreases and the emission peak shifts by approximately 30 nm. For two-photon detection, the excitation/emission wavelengths of Lyso-OC are 760/490-550 nm, and its one-photon excitation wavelength is 375 nm. Lyso-OC can be used in cancer-related research .
Cat. No.: HY-N0597R
CAS No.: 32791-84-7
Target:
Cat. No.: HY-N10116A
CAS No.: 483-77-2
Category:
Cat. No.: HY-N10133
CAS No.: 119240-82-3
Synonyms: 3′-Prenylnaringenin
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
